Business
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial ...
About this update from Revelation Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025.","length":338,"tagName":"p"},{"type":"text","content":"Corporate Highlights","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Received net proceeds of $6.7 million from warrant inducement in January 2026","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego (March 29 - April 1, 2026)","length":270,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":570,"olType":false},{"type":"text","content":""2025 was a positive year for Revelation with significant advancement of the Gemini program," said James Rolke, Chief Executive Officer of Revelation. "We look forward to building on this momentum in 2026 to expeditiously bring Gemini to patients in need and adding to shareholder value."","length":308,"tagName":"p"},{"type":"text","content":"Results of Operations","length":21,"tagName":"p"},{"type":"text","content":"As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The increase in cash and cash equivalents was primarily due to net cash proceeds from the May 2025 public offering and the September 2025 warrant inducement, offset by cash used for operating activities. Based on current operating plans and projections, Revelation believes its current cash and cash equivalents are sufficient to fund operations into the first quarter of 2027.","length":511,"tagName":"p"}...